Brands: Lasix · Furosemide
Average across 41 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Bryant Ranch Prepack | repackager | 58 | SUPPLYING |
| Aphena Pharma Solutions - Tennessee, LLC | repackager | 46 | SUPPLYING |
| A-S Medication Solutions | repackager | 36 | SUPPLYING |
| PD-Rx Pharmaceuticals, Inc. | repackager | 22 | SUPPLYING |
| NuCare Pharmaceuticals,Inc. | repackager | 18 | SUPPLYING |
| Proficient Rx LP | repackager | 14 | SUPPLYING |
| NCS HealthCare of KY, LLC dba Vangard Labs | repackager | 13 | SUPPLYING |
| Solco Healthcare US, LLC | unknown | 12 | SUPPLYING |
| Preferred Pharmaceuticals Inc. | repackager | 12 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 11 | SUPPLYING |
| Northwind Health Company, LLC | repackager | 11 | SUPPLYING |
| Ipca Laboratories Limited | unknown | 10 | SUPPLYING |
| Marlex Pharmaceuticals Inc | unknown | 9 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | generic | 9 | SUPPLYING |
| Granulation Technology, Inc. | unknown | 9 | SUPPLYING |
+ 16 more labelers
Shortages, recalls, and registration changes attached to this drug concept.
Furosemide Oral Solution — reported in shortage by Hikma Pharmaceuticals USA, Inc.. Therapeutic category: Cardiovascular.
CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit. — Recalling firm: Leading Pharma, LLC — US Nationwide.
Presence of Foreign Substance — Recalling firm: Graviti Pharmaceuticals Private Limited — U.S. Nationwide
Failed Tablet/Capsule Specifications: An unusually thick tablet was reported through a complaint. — Recalling firm: Roxane Laboratories, Inc. — Nationwide in the USA
CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP. — Recalling firm: Boehringer Ingelheim Roxane Inc — Nationwide and Puerto Rico
CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP. — Recalling firm: Boehringer Ingelheim Roxane Inc — Nationwide and Puerto Rico
